Pexiganan-incorporated collagen matrices for infected wound-healing processes in rat.
The use of peptide-based drugs is limited by their rapid degradability and toxicity at high concentration during their therapeutic application. These problems could be managed by the use of a peptide delivery agent for sustained release in the site of action. Collagen is one of the most proven biomaterials of good biocompatibility with an exceptional ligand encapsulating property. In this work, we have shown that pexiganan, an antimicrobial, 22-amino-acid peptide could be incorporated and delivered to the wound-healing site against bacterial strains Pseudomonas aeruginosa and Staphylococcus aureus. The release profiles of pexiganan collagen films with different collagen concentration were studied. The release of pexiganan from 2.5% w/w of collagen film showed a sustainable activity over 72 h with effective antimicrobial concentrations. Pexiganan-incorporated collagen (PIC)-treated groups were compared with open wound (OW)- and collagen film (CF)-treated rats. PIC-treated animals showed a diminishing level of bacterial growth as compared with OW- and CF-treated animals. The biochemical parameters such as hydroxyproline, protein, DNA, uronic acid, hexosamine, SOD, and catalase content in the granulation tissue of the healing wound revealed increased proliferation of cells involved in tissue reconstruction in PIC-treated groups when compared with OW- and CF-treated groups. Furthermore, spectroscopic studies suggested that collagen structure is not perturbed by pexiganan incorporation. This study provides rationale for application of collagen membrane for antimicrobial peptide delivery in infected wounds.
Gopinath
D
D
Bio-Organic & Neurochemistry Laboratory, Central Leather Research Institute, Adyar, Chennai, India.
Kumar
M Senthil
MS
Selvaraj
D
D
Jayakumar
R
R
D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000378:metabolism; D002942:Circular Dichroism; D003094:Collagen / Q000378:metabolism*; D016503:Drug Delivery Systems; D008422:Materials Testing; D008826:Microbial Sensitivity Tests; D017433:Protein Structure, Secondary; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D051381:Rats; D017550:Spectroscopy, Fourier Transform Infrared; D013211:Staphylococcus aureus / Q000187:drug effects; D014945:Wound Healing; D014946:Wound Infection / Q000188:drug therapy
D023181:Antimicrobial Cationic Peptides; D001672:Biocompatible Materials; D003094:Collagen; C093828:pexiganan